YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Glaukos Corporation GKOS recently announced a licensing agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases. The agreement grants Glaukos ex…
Bruker Corporation BRKR has witnessed strong momentum over the past year. Shares of the company have risen 66.3% compared with the industry's 66.4% growth. The S&P 500 composite has increased 18.2% during the same time frame. With healthy…
10x Genomics, Inc. TXG recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biom…
Waters WAT is well-poised for growth in the coming quarters, driven by sustained demand for analytical sciences, an extended instrument replacement cycle, BD integration and synergies, product innovation and growing opportunities in biosep…
Becton, Dickinson and Company BDX, popularly known as BD, recently announced a landmark partnership with the U.S. Government to expand domestic manufacturing of essential medical consumables and strengthen healthcare supply-chain resilienc…
Globus Medical, Inc. GMED is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments. Also, product innovation and so…
Merit Medical Systems, Inc. MMSI is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid product performance, global expansion and strategic M&A, is expected to contribute furt…
GE HealthCare Technologies Inc. GEHC recently announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, for $945 million in cash. The acq…
OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuri…
OPKO Health, Inc.'s OPK shares have jumped 32.5% year to date, showing impressive momentum. It has significantly outperformed the industry's 6.9% decline and the S&P 500's 11.5% gain. With healthy fundamentals and strong growth opportuniti…
Earlier this month, OPKO Health expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes backed by future mazdutide royalty payments from China, allowing it to raise capital without issu…
On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 dr…
Friday, September 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Marvell Technology,…
OPKO Health, Inc. MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, toda…
It has been about a month since the last earnings report for Steris (STE). Shares have lost about 2.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is…
It has been about a month since the last earnings report for Waters (WAT). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is W…
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at…
It has been about a month since the last earnings report for OPKO Health (OPK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, o…
OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuri…
[Patients Receiving Medical Infusions in a Clinical Setting with Nurse Assistance] FatCamera/iStock via Getty Images Earlier this week, shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and partner Merck (MRK [https://seeking…
By David Bautz, PhD NASDAQ: COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Approaches Key Readout Cocrystal Pharma, Inc. (NASDAQ: COCP) is continuing its Phase 1b human challenge study of CDI-988 to evaluate its potential…
OPKO Health, Inc. OPK secured $125 million of additional financing against mazdutide royalties, adding non-dilutive capital while keeping long-term participation in royalty growth in China. The transaction extends OPK's use of royalty-back…
OPKO Health, Inc. OPK combines a discounted forward sales multiple with improving operating trends, but the investment case remains balanced by ongoing losses and substantial clinical-development risk. The shares look inexpensive against i…
OPKO Health, Inc. OPK shares have gained 12.4% in the past four weeks, putting recent operating improvement and upcoming clinical milestones in focus. The rally has support from narrower losses, better margins and favorable estimate revisi…
OPKO Health OPK expanded its strategic financing relationship with HealthCare Royalty (HCRx) by issuing $125 million of senior secured notes backed by its royalty interests from the mazdutide license agreement with Eli Lilly. The transacti…
OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) t…
(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further,…
OPKO Health (OPK) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock pric…
Cocrystal Pharma, Inc. Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocryst…
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue…
OPKO Health, Inc. reported its second-quarter 2026 results on July 27, 2026, with revenue of US$163.58 million and a net loss of US$8.42 million, alongside updated guidance calling for total revenue of US$131 million to US$142 million for…
Opko Health (NASDAQ: OPK) was one of the healthier stocks on the exchange Tuesday. Its price zoomed more than 33% higher, on the back of a very well-received quarterly earnings report that beat on both trailing results and annual guidance.…
Key Points Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the raised full-year revenue guidance.10 stocks we like better than Opko Health › Opko Health(NASDAQ: OPK) was one of the healthier stoc…
OPKO Health, Inc. OPK reported a second-quarter 2026 loss of 1 cent per share, narrower than the year-ago quarter's loss of 19 cents. The figure beat the Zacks Consensus Estimate of a loss of 8 cents by 87.5%. Revenues rose 4.3% year over…
[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures showed mixed activity Tuesday morning as investors awaited key technology sector earnings that could shape the outlook for artificial int…
This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million i…